FIREFLY NEUROSCIENCE, INC.

Proxy Statement on Schedule 14A, as filed with the Securities and Exchange Commission on January 21, 2025 (the “Proxy Statement”), the relevant portions of which are incorporated by reference herein. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company’s stockholders at the Special Meeting.

(i) A proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of 20% or more of our issued and outstanding common stock of the Company, pursuant to the Securities Purchase Agreement, dated as of December 20, 2024, between the Company and Helena Special Opportunities LLC (“Helena”), including upon the conversion of a convertible note issued to Helena and upon the exercise of a warrant issued to Helena. The proposal was approved as set forth below:

(ii) A proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of 20% or more of our issued and outstanding common stock pursuant to the Purchase Agreement, dated December 20, 2024, between the Company and Arena Business Solutions Global SPC II, Ltd. The proposal was approved as set forth below:

(d) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.